HC Wainwright Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $40.00
Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price objective trimmed by HC Wainwright from $75.00 to $40.00 in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a neutral rating on the biotechnology company’s stock. SRPT has been the topic of several other reports. Wells Fargo & Company initiated coverage on […]
Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price objective trimmed by HC Wainwright from $75.00 to $40.00 in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a neutral rating on the biotechnology company’s stock. SRPT has been the topic of several other reports. Wells Fargo & Company initiated coverage on […]
